tocilizumab   Click here for help

GtoPdb Ligand ID: 6881

Synonyms: Actemra® | R-1569 | RG-1569 | RHPM-1 | RoActemra®
Approved drug Immunopharmacology Ligand
tocilizumab is an approved drug (FDA (2010), EMA (2009))
Compound class: Antibody
Comment: Tocilizumab is an anti-IL-6 receptor mAb, with immunosuppressive action [11] that is approved for chronic autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Qyuns Therapeutics have a potential tocilizumab biosimilar (QX003S) in Phase 1 evaluation for rheumatoid arthritis (trial registry number ChiCTR1900021808).

SARS-CoV-2 and COVID-19: In early March 2020, China's National Health Commission issued guidance that allows use of tocilizumab to treat patients with serious COVID-19-induced lung damage. Tocilizumab is predicted to mitigate against the uncontrolled immune response that is triggered by SARS-CoV-2 infection [3,15] in some patients and which leads to potentially life-threatening damage to the lungs and other organs. Clinical trials are beginning to reveal outcomes (Oct 2020), but the level of benefit remains unclear [4-5,12-13] and requires further investigations. Differences between the studies (timing of treatment, severity of disease at initiation of treatment etc.) make it difficult to compare results and form a solid conclusion.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: tocilizumab

Immunopharmacology Comments
Tocilizumab blocks IL-6R activation, which in turn leads to a reduction in cytokine and acute phase reactant production, and eventual symptomatic relief.
Immunopharmacology Disease
Disease X-Refs Comment References
Temporal arteritis Disease Ontology: DOID:13375
OMIM: 187360
Orphanet: ORPHA397
Approved drug for temporal (giant cell) arteritis (May 2017). 14
Juvenile idiopathic arthritis- systemic OMIM: 604302
An anti-IL-6 therapy approved for sJIA.
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Tocilizumab was the first humanized mAb to be developed against human IL-6 receptors, and is now an approved therapeutic for RA.
Immunopaedia Case Studies Links
A case of lymphadenopathy and night sweats